Linked Data API

Show Search Form

Search Results

1138094
star this property registered interest false more like this
star this property date less than 2019-07-10more like thismore than 2019-07-10
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
unstar this property answering dept sort name Health and Social Care more like this
star this property hansard heading Irritable Bowel Syndrome: Cannabis more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of using medicinal cannabis to treat Irritable Bowel Syndrome. more like this
star this property tabling member constituency Brigg and Goole more like this
star this property tabling member printed
Andrew Percy more like this
unstar this property uin 275738 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-07-18more like thismore than 2019-07-18
unstar this property answer text <p>An initial impact assessment Rescheduling of cannabis-based products for medicinal use under the Misuse of Drugs Regulations 2001 was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. A copy of this impact assessment is available at the following link:</p><p> </p><p><a href="http://www.legislation.gov.uk/uksi/2018/1055/impacts" target="_blank">http://www.legislation.gov.uk/uksi/2018/1055/impacts</a></p><p> </p><p>This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of CBPM. The analysis is limited to the five medical conditions where there is most evidence. These five conditions are multiple sclerosis – pain or muscle spasticity; chemotherapy-induced nausea and vomiting; severe treatment-resistant epilepsy in children - specifically Dravet Syndrome and Lennox-Gastaut Syndrome only; chronic pain in adults and appetite and weight loss associated with HIV/AIDS.</p><p>To further the evidence-base, the National Institute for Health Research has issued two calls for research in this area and is working with the industry and researchers to ensure that the evidence is developed in a way that will inform decisions on public funding. This research will be open to all good quality proposals covering any indication, including pain and other disorders unresponsive to existing treatments.</p><p> </p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy remove filter
star this property grouped question UIN 275737 remove filter
star this property question first answered
less than 2019-07-18T09:33:54.507Zmore like thismore than 2019-07-18T09:33:54.507Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
3939
unstar this property label Biography information for Andrew Percy more like this